All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Cortisol, oxytocin, and women's hormones: fact vs. TikTok

Dr. Jolene Brighten

TikTok creator

3.1M viewsWatch on TikTok

Quick answer

The video describes the Dual Control Model of sexual response, a framework with substantial empirical support showing that sexual inhibition, not just lack of excitation, drives low desire in many women. Chronic psychosocial stress elevates cortisol and can suppress endogenous testosterone production, creating a neuroendocrine pathway between everyday stressors and reduced libido that is clinically relevant for patients on hormone optimization protocols. Women presenting with low desire on a TRT or hormone platform should be screened for inhibition-system drivers, including stress load and relationship context, not just androgen levels.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

TRT social video fact-checksMedical claim reviewProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Access rules depend on the compound and patient situation

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 11 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For Cortisol, oxytocin, and women's hormones: fact vs. TikTok, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

Cortisol, oxytocin, and women's hormones: fact vs. TikTok is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Claim path

Keep researching this testosterone and trt video claims cluster

Best for searchers turning TRT social claims into a safer lab-backed provider discussion.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "Cortisol, oxytocin, and women's hormones: fact vs. TikTok" from Dr. Jolene Brighten. We read the clip as a TRT social video fact-checks claim about Testosterone, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: The video describes the Dual Control Model of sexual response, a framework with substantial empirical support showing that sexual inhibition, not just lack of excitation, drives low desire in many women.

The reason this review is not generic is the source wording and the canonical claim label "trt hormones can be why you feel the way you do but when it come." In this clip, the useful excerpt is: "Hormones can be why you feel the way you do, but when it comes to the research on women, it shows us that it can be a lot more complicated." That wording changes the review because it points to Testosterone evidence, safety, and patient-fit context, not a one-size-fits-all protocol.

The source trail for this page is checked against Cardiovascular Safety of Testosterone-Replacement Therapy (2023), Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline (2010), and Functional testosterone deficiency in aging men: Clinical impact, diagnostic pathways, and treatment strategies (2026), plus the creator's own wording. Testosterone decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

Bancroft et al.
People who land here are usually comparing the Testosterone claim with [object Object].
The strongest next step is to compare the claim with FormBlends' Testosterone guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

The video describes the Dual Control Model of sexual response, a framework with substantial empirical support showing that sexual inhibition, not just lack of excitation, drives low desire in many women.

FormBlends verdict

Testosterone evidence, safety, and patient-fit context

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • The video describes the Dual Control Model of sexual response, a framework with substantial empirical support showing that sexual inhibition, not just lack of excitation, drives low desire in many women. Chronic psychosocial stress elevates cortisol and can suppress endogenous testosterone production, creating a neuroendocrine pathway between everyday stressors and reduced libido that is clinically relevant for patients on hormone optimization protocols. Women presenting with low desire on a TRT or hormone platform should be screened for inhibition-system drivers, including stress load and relationship context, not just androgen levels.
  • The Dual Control Model, developed by Bancroft and Janssen at the Kinsey Institute, is peer-reviewed science, not a pop metaphor. It measures both excitation and inhibition as independent systems.
  • Bancroft et al. (2003) found inhibition scores predicted low sexual interest in women more strongly than excitation deficits alone, supporting the 'brakes over gas' argument.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compound access, legal status, and product quality still need a separate safety check.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.

Start provider review

What You'll Learn

  • The Dual Control Model, developed by Bancroft and Janssen at the Kinsey Institute, is peer-reviewed science, not a pop metaphor. It measures both excitation and inhibition as independent systems.
  • Bancroft et al. (2003) found inhibition scores predicted low sexual interest in women more strongly than excitation deficits alone, supporting the 'brakes over gas' argument.
  • Chronic stress elevates cortisol, which can suppress hypothalamic GnRH signaling and downstream testosterone production in women, creating a direct neuroendocrine link between daily stress and low libido.
  • Oxytocin does appear to modulate HPA axis stress responses, but the effect is context-dependent and not as simple as 'oxytocin shuts off cortisol.' Heinrichs et al. (2003) showed the effect required both oxytocin and social support together.
  • Meston and Buss (2007, Archives of Sexual Behavior) documented 237 distinct reasons people have sex, including stress reduction, confirming that motivation for sex is far more varied than the purely desire-driven model most people assume.
  • For patients on hormone optimization protocols presenting with low libido, a stress and cortisol assessment is clinically relevant alongside testosterone levels. The two systems interact.
  • The gas-and-brakes framework has practical clinical utility: asking what is blocking desire often yields more actionable answers than asking what is missing from it.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.

What did @drjolenebrighten actually say?

Dr. Jolene Brighten, a naturopathic physician and author, laid out a framework for why women's sexual desire works differently from men's. Her core argument: women don't just need more stimulation to want sex, they need fewer obstacles. She invoked oxytocin as a cortisol counterweight, described a 'sexual excitation and inhibition model' with a gas pedal and brakes metaphor, and argued that 'what women mostly need is dampening of the brakes.' Everyday stressors, she said, pile up like blockades on a train track, preventing arousal signals from reaching the brain.

She also made a pointed observation about heterosexual relationship dynamics: that partners often try to accelerate desire directly (lingerie, candles) when the more effective move is reducing what's already hitting the brakes. The video is framed around her book Is This Normal? and targets a general audience, not clinicians.

Does the science back this up?

Mostly, yes. The model she's describing is real, well-researched, and actually underrepresented in popular health content. The Dual Control Model was developed by Bancroft and Janssen at the Kinsey Institute in the early 2000s and has been extended substantially by Emily Nagoski and researcher Erick Janssen. The core idea, that sexual response is regulated by both an excitation system and an inhibition system, has solid empirical grounding.

Chivers et al. (2010, Psychological Bulletin) found that women show more variability in the relationship between genital response and subjective arousal than men, which supports the idea that psychological context plays a heavier role in women's desire. Bancroft et al. (2003, Archives of Sexual Behavior) demonstrated that high inhibition scores predicted low sexual interest in women more reliably than low excitation scores alone. That's exactly what Brighten is saying: the brake, not the accelerator, is the bigger variable for most women.

Her oxytocin-versus-cortisol framing is a rougher approximation of reality, but the directional claim isn't wrong.

What did they get wrong (or right)?

The oxytocin claim deserves some scrutiny. Brighten implies oxytocin reliably suppresses cortisol stress responses, framing it as almost competitive: 'oxytocin will be like, shut up cortisol.' That's an oversimplification. Oxytocin does appear to modulate the HPA axis stress response, and studies like Heinrichs et al. (2003, Neuropsychopharmacology) showed intranasal oxytocin plus social support reduced cortisol reactivity. But the relationship is context-dependent, and endogenous oxytocin levels during sex are notoriously hard to measure and interpret. Saying women 'enter into sex' specifically because oxytocin will neutralize cortisol is a pop-science shortcut, not a clinical mechanism.

The gendered framing, 'for most men' versus 'most women,' is presented with more certainty than the data supports. The Dual Control Model applies to all people, and there's meaningful variation within genders. Some men have highly sensitive inhibition systems; some women have high excitation sensitivity. Brighten's framing, while useful for a general audience, risks reinforcing the idea that these patterns are fixed rather than distributed on a spectrum.

What she got right: the specific list of inhibitors she names (emotional dismissal, unmet requests, work stress, physical environment) maps directly onto inhibition factors documented in Brotto et al. (2016, Journal of Sexual Medicine). That's not anecdote. That's the research.

What should you actually know?

The Dual Control Model is one of the more clinically useful frameworks in sexual medicine that most people have never heard of. If you're a patient experiencing low desire, or a clinician seeing it, the reflex is often to ask 'what's missing?' when the more productive question is 'what's getting in the way?' Those are different clinical problems with different solutions.

Stress is not a minor variable here. Meston and Buss (2007, Archives of Sexual Behavior) catalogued 237 reasons people have sex, and stress reduction appeared as a real motivator, particularly among women. Chronic cortisol elevation is also associated with suppressed testosterone, which is directly relevant on a hormone optimization platform. Low testosterone in women is associated with reduced desire, and the stressors Brighten describes aren't just psychological, they're neuroendocrine.

  • If low desire is the presenting concern, a cortisol and testosterone workup is worth having before assuming the issue is purely relational.
  • The inhibition system is not a character flaw. It's a nervous system state, and it responds to systemic intervention, not just communication tips.
  • Partners who want to address desire gaps should look at what's creating inhibition, not just what they can add.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Dr. Jolene Brighten · TikTok creator

3.1M views on this video

Hormones can be why you feel the way you do, but when it comes to the research on women, it shows us that it can be a lot more complicated. #cortisol #oxytocin #oxytocinrelease #oxytocinboost #hormonehealth #womenshealth #whatwomenwant #whatwomenreallywant #latinaauthors #isthisnormalbook

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the evidence say about the dual control model, developed by bancroft?

The Dual Control Model, developed by Bancroft and Janssen at the Kinsey Institute, is peer-reviewed science, not a pop metaphor. It measures both excitation and inhibition as independent systems.

What does the evidence say about bancroft et al. (2003) found inhibition scores predicted low sexual?

Bancroft et al. (2003) found inhibition scores predicted low sexual interest in women more strongly than excitation deficits alone, supporting the 'brakes over gas' argument.

What does the evidence say about chronic stress elevates cortisol?

Chronic stress elevates cortisol, which can suppress hypothalamic GnRH signaling and downstream testosterone production in women, creating a direct neuroendocrine link between daily stress and low libido.

What does the evidence say about oxytocin does appear to modulate hpa axis stress responses?

Oxytocin does appear to modulate HPA axis stress responses, but the effect is context-dependent and not as simple as 'oxytocin shuts off cortisol.' Heinrichs et al. (2003) showed the effect required both oxytocin and social support together.

What does the evidence say about meston?

Meston and Buss (2007, Archives of Sexual Behavior) documented 237 distinct reasons people have sex, including stress reduction, confirming that motivation for sex is far more varied than the purely desire-driven model most people assume.

What does the evidence say about for patients on hormone optimization protocols presenting with low libido?

For patients on hormone optimization protocols presenting with low libido, a stress and cortisol assessment is clinically relevant alongside testosterone levels. The two systems interact.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Not medical advice. This video was made by Dr. Jolene Brighten, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.